DATA GRAPHICS | Data Byte
Plus: Agency approves Pfizer’s hemophilia A and B mAb, and label expansions for five products
By Gunjan Ohri, Data Content Analyst
November 9, 2024 1:23 AM UTC
FDA approved six new medicines in October, including the U.S.’s first CLDN18.2-targeting cancer therapy, and expanded labels for five approved therapies.
Astellas Pharma Inc. (Tokyo:4503) has followed up is Japan approval of CLDN18.2 mAb Vyloy zolbetuximab, which marked the first approval of a therapy against the target worldwide, with an approval in the U.S. At least 32 other CLDN18.2 therapies are in clinical studies…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654130/fda-s-october-approvals-include-the-first-cldn18-2-mab